Location of Repository

Angiotensin II Induced Premature Senescence of Human Vascular Smooth Muscle Cells

By Yogita Mistry


Senescence is a state of irreversible growth arrest in cells with potentially tumourigenic changes such as irreparable DNA damage. However, senescent cells accumulate with age, altering tissue structure and function and have been observed in atherosclerotic plaques and at sites predisposed to atheroma in man. Recent studies show that long term inhibition of the renin-angiotensin system attenuates the effects of ageing in rodent cardiovascular tissue. Therefore, this thesis investigated whether angiotensin II accelerates senescence of human vascular smooth muscle cells (hVSMC) in vitro and whether the mechanism involves reactive oxygen species, DNA damage, telomere attrition and cell cycle regulatory proteins. Since mitochondria are integral to theories of cellular ageing, the effect of angiotensin II on mitochondrial biogenesis and function were studied. Angiotensin II exposure enhanced superoxide generation via NADPH oxidase in hVSMC, although inhibitors identified the mitochondrial respiratory chain as a contributing source. Angiotensin II induced DNA stand breaks in the Comet assay and accelerated telomere attrition. Senescence associated-β-galactosidase activity was induced by angiotensin II after exposure for 30 days, but also after just 24 hours and after successive short treatments over three days. These effects were attenuated by an angiotensin II type-1 receptor antagonist and antioxidants. Simultaneously, increased expression of p21 and p53 were observed. Angiotensin II induced alterations in mitochondria. A rapid increase in mtDNA content, gene transcript levels involved in initiating mtDNA transcription and replication and ATP levels in hVSMC, suggested mitochondrial biogenesis occurs in response to stress. These data suggest that angiotensin II induces both accelerated replicative senescence (telomere-dependent) and stress-induced premature senescence (telomere-independent) of hVSMC, dependent upon the treatment regime used. These findings explain the anti-ageing effects of life-long angiotensin II blockade in rodents, and may provide a mechanism for accelerated vascular ageing and cardiovascular disease progression in the ageing human population

Publisher: University of Leicester
Year: 2009
OAI identifier: oai:lra.le.ac.uk:2381/9544

Suggested articles



  1. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
  2. (2003). A DNA damage checkpoint response in telomere-initiated senescence.
  3. (2004). A fluorimetric method using fluorescein di-beta-Dgalactopyranoside for quantifying the senescence-associated beta-galactosidase activity in human foreskin fibroblast Hs68 cells.
  4. (1993). A monoclonal antibody to a conserved sequence in the extracellular domain recognizes the angiotensin II AT1 receptor in mammalian target tissues.
  5. (2005). A mouse model of Werner Syndrome: what can it tell us about aging and cancer?
  6. (2001). A new mathematical model for relative quantification in real-time RT-PCR.
  7. (2008). A quantitative chemiluminescent method for studying replicative and stress-induced premature senescence in cell cultures.
  8. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
  9. (2002). A role for mitochondria as potential regulators of cellular life span.
  10. (1988). A simple technique for quantitation of low levels of DNA damage in individual cells.
  11. (2002). A two-stage, p16 (INK4A) - and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status.
  12. (2002). Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy.
  13. (2000). Accelerated replicative senescence of medial smooth muscle cells derived from abdominal aortic aneurysms compared to the adjacent inferior mesenteric artery.
  14. (2004). Accelerated telomere shortening in response to life stress.
  15. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.
  16. (1984). Actin expression in smooth muscle cells of rat aortic intimal thickening, human atheromatous plaque, and cultured rat aortic media.
  17. (2002). Advances in our understanding of aging: role of the renin-angiotensin system.
  18. (1995). Age-related changes in vascular responses: a review.
  19. (2001). Age-related mitochondrial genotypic and phenotypic alterations in human skeletal muscle.
  20. (2003). Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates.
  21. (2004). Aging of cardiac myocytes in culture: oxidative stress, lipofuscin accumulation, and mitochondrial turnover.
  22. (1996). Aging-dependent functional alterations of mitochondrial DNA (mtDNA) from human fibroblasts transferred into mtDNA-less cells.
  23. (2003). Aging, progenitor cell exhaustion, and atherosclerosis.
  24. (1956). Aging: a theory based on free radical and radiation chemistry.
  25. (2008). Aginginduced alterations in gene transcripts and functional activity of mitochondrial oxidative phosphorylation complexes in the heart.
  26. (2004). Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway.
  27. (2007). Alterations of cellular bioenergetics in pulmonary artery endothelial cells.
  28. (2006). An accelerated senescence response to radiation in wild-type p53 glioblastoma multiforme cells.
  29. (2006). ANG II induces apoptosis of human vascular smooth muscle via extrinsic pathway involving inhibition of Akt phosphorylation and increased FasL expression.
  30. (2003). Ang II is also reported to promote apoptosis during disease progression (Taniyama and Griendling,
  31. (1999). Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells.
  32. (2005). Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress.
  33. (2004). Angiotensin II and cell cycle regulation.
  34. (2004). Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells.
  35. (2005). Angiotensin II and the endothelium: diverse signals and effects.
  36. (2007). Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system.
  37. (1995). Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms: evidence for homologous and heterologous regulation.
  38. (2008). Angiotensin II induces endothelial cell senescence via the activation of mitogen-activated protein kinases.
  39. Angiotensin II induces human vascular smooth muscle cell senescence via reactive oxygen species generation. Free Radic Biol Med 39 (Suppl.1),
  40. (1999). Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors.
  41. (2006). Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway.
  42. (2005). Angiotensin II induces proliferation of human cerebral artery smooth muscle cells through a basic fibroblast growth factor (bFGF) dependent mechanism.
  43. (1995). Angiotensin II receptor antagonism: Losartan - sites and mechanisms of action.
  44. (2000). Angiotensin II receptor antagonists.
  45. (1997). Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation.
  46. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.
  47. (2002). Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators.
  48. (1998). Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer study.
  49. (2007). Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging.
  50. (2001). Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice.
  51. (1999). Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPHoxidases.
  52. (2003). Angiotensin II: a vasoactive hormone with ever-increasing biological roles.
  53. (2007). Angiotensin IIinduced growth of vascular smooth muscle cells is associated with modulation of cell surface area and platelet-derived growth factor receptor expression.
  54. (2005). Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.
  55. (2001). Angiotensin receptors: distribution, signalling and function.
  56. (2005). Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution.
  57. (1996). Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases.
  58. (1994). Angiotensinogen-deficient mice with hypotension.
  59. (2001). Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR.
  60. (2008). Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant.
  61. (2000). Apoptosis or senescence-like growth arrest: influence of cell-cycle position, p53, p21 and bax in H2O2 response of normal human fibroblasts.
  62. (2005). Arterial aging: is it an immutable cardiovascular risk factor?
  63. (2003). Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease.
  64. (2003). Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development.
  65. (2008). Association between oxidative DNA damage and telomere shortening in circulating endothelial progenitor cells obtained from metabolic syndrome patients with coronary artery disease.
  66. (2007). Association between telomere length and heart disease in a narrow age cohort of older people.
  67. (2003). Association between telomere length in blood and mortality in people aged 60 years or older.
  68. (2004). Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension.
  69. (2007). Association of telomere shortening with impaired glucose tolerance and diabetic macroangiopathy.
  70. (2003). ATM and related protein kinases: safeguarding genome integrity.
  71. (1994). Augmentation of intrarenal angiotensin II levels by chronic angiotensin II infusion.
  72. (1992). Beta-adrenergic responsiveness in cultured aorta smooth muscle cells. Effects of subculture and aging.
  73. (2008). Biological ageing and cardiovascular disease.
  74. (1990). Blood glucose area under the curve. Methodological aspects.
  75. (2008). Blood leucocyte telomere DNA content predicts vascular telomere DNA content in humans with and without vascular disease.
  76. (2007). Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms.
  77. (2003). Calcitonin gene-related peptide partly protects cultured smooth muscle cells from apoptosis induced by an oxidative stress via activation of ERK1/2 MAPK.
  78. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease.
  79. (2007). Calorie restriction increases muscle mitochondrial biogenesis in healthy humans.
  80. (2004). Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.
  81. (2002). Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
  82. (2005). Caveolin-1 is essential for activation of Rac1 and NAD(P)H oxidase after angiotensin II type 1 receptor stimulation in vascular smooth muscle cells: role in redox signaling and vascular hypertrophy.
  83. (2001). Cell cycle checkpoint signaling through the ATM and ATR kinases.
  84. (2000). Cell signaling by reactive nitrogen and oxygen species in atherosclerosis.
  85. (2000). Cellular and molecular mechanisms of stress-induced premature senescence (SIPS) of human diploid fibroblasts and melanocytes.
  86. (2002). Cellular glutathione and thiols metabolism.
  87. (2008). Cellular responses to reactive oxygen species-induced DNA damage and aging.
  88. (2001). Cellular senescence after single and repeated balloon catheter denudations of rabbit carotid arteries.
  89. (2001). Cellular senescence as a tumor-suppressor mechanism.
  90. (2007). Cellular senescence in endothelial cells from atherosclerotic patients is accelerated by oxidative stress associated with cardiovascular risk factors.
  91. (2005). Cellular senescence in vivo: its relevance in ageing and cardiovascular disease.
  92. (2008). Cellular senescence, cardiovascular risk, and CKD: a review of established and hypothetical interconnections.
  93. (2004). Chondrocyte senescence, joint loading and osteoarthritis.
  94. (2004). Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells.
  95. (2006). Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.
  96. (2005). Coexpression of AT1 and AT2 receptors by human fibroblasts is associated with resistance to angiotensin II.
  97. (2005). Comparison of replicative senescence and stress-induced premature senescence combining differential display and lowdensity DNA arrays.
  98. (2003). Constitutive activation of rac1 results in mitochondrial oxidative stress and induces premature endothelial cell senescence.
  99. (1998). Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques.
  100. (2003). Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1.
  101. (2007). Coronary artery aneurysm induced by Kawasaki disease in children show features typical senescence.
  102. (2007). Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence.
  103. (1999). Cultured porcine coronary artery smooth muscle cells. A new model with advanced differentiation.
  104. (2007). Cyclin D1 overexpression permits the reproducible detection of senescent human vascular smooth muscle cells.
  105. (1998). Cytochemical detection of a senescence-associated beta-galactosidase in endothelial and smooth muscle cells from human and rabbit blood vessels.
  106. (2005). Decline in skeletal muscle mitochondrial function with aging in humans.
  107. (2002). Decreased ATP-synthesis ability of liver mitochondria in spontaneously hypertensive rats (SHR): role of calcium overload of the mitochondria.
  108. (1997). Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms.
  109. (1993). Deglycosylation and fragmentation of purified rat liver angiotensin II receptor: application to the mapping of hormone-binding domains.
  110. (1997). Degradation of oxidized proteins in mammalian cells.
  111. (2004). Delayed ischemic preconditioning activates nuclear-encoded electron-transfer-chain gene expression in parallel with enhanced postanoxic mitochondrial respiratory recovery.
  112. (2005). Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice.
  113. (2003). Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles.
  114. (1999). Detection of mitochondria-derived reactive oxygen species production by the chemilumigenic probes lucigenin and luminol.
  115. (2002). Different telomere damage signaling pathways in human and mouse cells.
  116. (2001). Differential NADPH- versus NADH-dependent superoxide production by phagocyte-type endothelial cell NADPH oxidase.
  117. (1998). Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production.
  118. (1999). Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
  119. (2006). DNA damage and repair capacity by comet assay in lymphocytes of white-collar active smokers and passive smokers (non- and ex-smokers) at workplace.
  120. (2007). DNA damage, p53, apoptosis and vascular disease.
  121. (2003). Down-regulation and decreased activity of cyclin-dependent kinase 2 in H2O2-induced premature senescence.
  122. (1994). Down-regulation by growth factors of vascular smooth muscle angiotensin receptor gene expression.
  123. (2008). Dysregulation of mitochondrial biogenesis in vascular endothelial and smooth muscle cells of aged rats.
  124. (2001). Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging.
  125. (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial.
  126. (2000). Effects of valsartan on angiotensin II-induced migration of human coronary artery smooth muscle cells.
  127. (2003). Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation.
  128. (2002). Elevated levels of oxidative DNA damage in patients with coronary artery disease.
  129. (2003). Enalapril and losartan attenuate mitochondrial dysfunction in aged rats.
  130. (2005). Endothelial aging.
  131. (2002). Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction.
  132. (2002). Endothelial cells maintain a reduced redox environment even as mitochondrial function declines.
  133. (2005). Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension.
  134. epigenetic dysregulation in cancer.
  135. (2006). ERK1/2 pathway is involved in the inhibitory effect of crocetin on angiotensin II-induced vascular smooth muscle cell proliferation.
  136. (2003). Erosion of the telomeric single-strand overhang at replicative senescence.
  137. (2004). Essential role of limiting telomeres in the pathogenesis of Werner syndrome.
  138. (1994). Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme.
  139. (2007). Exercise-induced mitochondrial biogenesis begins before the increase in muscle PGC-1α expression.
  140. (1993). EXP3174, a metabolite of losartan
  141. (2002). Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II.
  142. (1992). Expression of angiotensin II AT2 receptors in the rat skin during experimental wound healing.
  143. (1998). Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins.
  144. (2002). Expression of human telomerase (hTERT) does not prevent stress-induced senescence in normal human fibroblasts but protects the cells from stress-induced apoptosis and necrosis.
  145. (2003). Extensive allelic variation and ultrashort telomeres in senescent human cells.
  146. (1994). Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry.
  147. (2006). Formation of elongated giant mitochondria in DFO-induced cellular senescence: involvement of enhanced fusion process through modulation of Fis1.
  148. (2002). From the Hayflick mosaic to the mosaics of ageing. Role of stress-induced premature senescence in human ageing.
  149. (2004). Gene expression and regulation in H2O2-induced premature senescence of human foreskin fibroblasts expressing or not telomerase.
  150. (2002). Giant mitochondria in a cardiomyopathic heart.
  151. (2001). Growth kinetics rather than stress accelerate telomere shortening in cultures of human diploid fibroblasts in oxidative stress-induced premature senescence.
  152. (1998). Growth response of human coronary smooth muscle cells to angiotensin II and influence of angiotensin AT1 receptor blockade.
  153. (2004). HaRas(G12V) induces senescence in primary and immortalized human esophageal keratinocytes with p53 dysfunction.
  154. (2000). Hayflick, his limit, and cellular ageing.
  155. (1998). Heterogeneous smooth muscle cell population derived from small and larger arteries.
  156. (2000). High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells.
  157. (2005). How to explain the differences between renin angiotensin system modulators.
  158. (2005). Human cell senescence as a DNA damage response.
  159. (2000). Human diploid fibroblasts display a decreased level of c-fos mRNA at 72 hours after exposure to sublethal H2O2 stress.
  160. (2000). Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells.
  161. (2008). Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a.
  162. (2008). Hypoxia activates NADPH oxidase to increase [ROS]i and [Ca 2+ ]i through the mitochondrial ROS-PKCepsilon signaling axis in pulmonary artery smooth muscle cells.
  163. (2001). Hypoxia extends the life span of vascular smooth muscle cells through telomerase activation.
  164. (2007). Identification of cultivation-independent markers of human endothelial cell senescence in vitro.
  165. (2006). Immunohistochemical detection of angiotensin receptors AT1 and AT2 in normal rat pituitary gland, estrogen-induced rat pituitary tumor and human pituitary adenomas.
  166. (2007). Importance of intracellular angiotensin II in vascular smooth muscle cell apoptosis: inhibition by the angiotensin AT1 receptor antagonist Irbesartan.
  167. (1997). Important role for angiotensin III and IV in the brain renin-angiotensin system.
  168. (2002). Increase in mitochondrial mass in human fibroblasts under oxidative stress and during replicative cell senescence.
  169. (2000). Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells.
  170. (2002). Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression.
  171. (2001). Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways.
  172. (2001). Increased hydroxyl radicals in the hippocampus of stroke-prone spontaneously hypertensive rats during transient ischemia and recirculation.
  173. (1999). Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system.
  174. (2007). Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism.
  175. (2000). Induction of replicative senescence biomarkers by sublethal oxidative stresses in normal human fibroblast.
  176. (2002). Initiator caspases in apoptosis signaling pathways.
  177. (2006). Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study.
  178. (2000). International union of pharmacology. XXIII. The angiotensin II receptors.
  179. (2005). Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II.
  180. (2000). Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries.
  181. (2001). Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis.
  182. (2005). Irreversible cellular senescence induced by prolonged exposure to H2O2 involves DNA-damage-and-repair genes and telomere shortening.
  183. (2000). Is beta-galactosidase staining a marker of senescence in vitro and in vivo?
  184. (2007). Knocking down p53 with siRNA does not affect the overexpression of p21 WAF-1 after exposure of IMR-90 hTERT fibroblasts to a sublethal concentration of H2O2 leading to premature senescence.
  185. (1993). Levels of angiotensin and molecular biology of the tissue renin angiotensin systems.
  186. (2001). Lipofuscin accumulation in proliferating fibroblasts in vitro: an indicator of oxidative stress.
  187. (1975). Long range periodicities in mouse satellite DNA.
  188. (1995). Male-female differences in fertility and blood pressure in ACE-deficient mice.
  189. (2005). Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells.
  190. (2007). Matrine induces apoptosis in angiotensin II-stimulated hyperplasia of cardiac fibroblasts: effects on Bcl-2/Bax expression and caspase-3 activation.
  191. (2000). Measurement of the ADP:ATP ratio in human leukaemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis.
  192. (2004). Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?
  193. (2000). Mechanical strain-induced extracellular matrix production by human vascular smooth muscle cells: role of TGF-beta(1).
  194. (2000). Mechanical straininduced human vascular matrix synthesis: the role of angiotensin II.
  195. (2007). Mechanisms of cardiovascular disease in accelerated aging syndromes.
  196. (2000). Mechanisms of increased susceptibility to angiotensin II-induced apoptosis in ventricular cardiomyocytes of spontaneously hypertensive rats.
  197. (2001). Mechanisms of telomerase induction during vascular smooth muscle cell proliferation.
  198. (2003). Metabolic analysis of senescent human fibroblasts reveals a role for AMP in cellular senescence.
  199. (1996). Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility.
  200. (1995). Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence?
  201. (2008). Mitochondria and premature senescence of vascular smooth muscle cells.
  202. (2005). Mitochondria-derived reactive oxygen species and vascular MAP kinases: comparison of angiotensin II and diazoxide.
  203. (2002). Mitochondria, nitric oxide, and cardiovascular dysfunction.
  204. (2005). Mitochondria, telomeres and cell senescence.
  205. (2001). Mitochondrial alterations, cellular response to oxidative stress and defective degradation of proteins in aging.
  206. (2004). Mitochondrial biogenesis by ·NO yields functionally active mitochondria in mammals.
  207. (2003). Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide.
  208. (2008). Mitochondrial biogenesis in the pulmonary vasculature during inhalational lung injury and fibrosis.
  209. (2000). Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease.
  210. (1997). Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress.
  211. (2008). Mitochondrial DNA damage triggers mitochondrial-superoxide generation and apoptosis.
  212. (2007). Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence.
  213. (2007). Mitochondrial fission and fusion mediators, hFis1 and OPA1, modulate cellular senescence.
  214. (2002). Mitochondrial integrity and function in atherogenesis.
  215. (2004). Mitochondrial signaling: the retrograde response.
  216. (2000). Mitochondrial uncoupling proteins: from mitochondria to the regulation of energy balance.
  217. (2007). Mitochondrial-nuclear communications.
  218. (2004). Modulation of oxidant and antioxidant enzyme expression and function in vascular cells.
  219. (1998). Modulation of the vascular smooth muscle angiotensin subtype 2 (AT2) receptor by angiotensin II.
  220. (1998). Molecular analysis of H2O2-induced senescent-like growth arrest in normal human fibroblasts: p53 and Rb control G1 arrest but not cell replication.
  221. (1993). Molecular cloning and characterization of the angiotensin receptor subtype in porcine aortic smooth muscle.
  222. (2002). Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent.
  223. (2008). Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction.
  224. (2003). Molecular mechanisms of replicative senescence in endothelial cells.
  225. (2004). Molecular regulation of vascular smooth muscle cell differentiation in development and disease.
  226. (2006). Monocyte telomere shortening and oxidative DNA damage in type 2 diabetes.
  227. (2005). NAD(P)H oxidase 4 mediates transforming growth factorbeta1-induced differentiation of cardiac fibroblasts into myofibroblasts.
  228. (2005). NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries.
  229. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
  230. (1997). Nonpeptide angiotensin II antagonist Losartan inhibits thromboxane A2-induced contractions in canine coronary arteries.
  231. (1990). Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.
  232. (2007). Normal or stress-induced fibroblast senescence involves COX-2 activity.
  233. (2006). Nuclear and mitochondrial genome responses in HeLa cells treated with inhibitors of mitochondrial DNA expression.
  234. (1995). Nuclear changes in apoptosis.
  235. (2005). Obesity, cigarette smoking, and telomere length in women.
  236. (2006). Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication.
  237. (2002). Oncogenic ras and p53 cooperate to induce cellular senescence.
  238. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16 INK4a .
  239. (2002). Overestimation of NADH-driven vascular oxidase activity due to lucigenin artifacts.
  240. (2002). Overexpression of apolipoprotein J in human fibroblasts protects against cytotoxicity and premature senescence induced by ethanol and tert-butylhydroperoxide.
  241. (2004). Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice.
  242. (2003). Oxidant stress: a key determinant of atherothrombosis.
  243. (2003). Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension.
  244. (2001). Oxidative damage to mitochondria and aging.
  245. (1995). Oxidative DNA damage and senescence of human diploid fibroblast cells.
  246. (1999). Oxidative DNA damage processing in nuclear and mitochondrial DNA.
  247. (2001). Oxidative stress and vascular damage in hypertension.
  248. (2006). Oxidative stress induces H2AX phosphorylation in human spermatozoa.
  249. (2002). Oxidative stress shortens telomeres.
  250. (2003). Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts.
  251. (2005). p53-dependent ICAM-1 overexpression in senescent human cells identified in atherosclerotic lesions.
  252. (2008). p53-related apoptosis resistance and tumor suppression activity in UVB-induced premature senescent human skin fibroblasts.
  253. (2007). Partial uncoupling of oxidative phosphorylation induces premature senescence in human fibroblasts and yeast mother cells.
  254. (1999). Permanent cell cycle arrest in asynchronously proliferating normal human fibroblasts treated with doxorubicin or etoposide but not camptothecin.
  255. (2004). PGC-1α mRNA expression is influenced by metabolic perturbation in exercising human skeletal muscle.
  256. (2002). Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes.
  257. (2000). Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage.
  258. (2003). Precise determination of mitochondrial DNA copy number in human skeletal and cardiac muscle by a PCR-based assay: lack of change of copy number with age.
  259. (2004). Preconditioning improves postischemic mitochondrial function and diminishes oxidation of mitochondrial proteins.
  260. (2005). Pregnancy and ovarian steroid regulation of angiotensin II type 1 and type 2 receptor expression in ovine uterine artery endothelium and vascular smooth muscle.
  261. (2004). Premature ageing in mice expressing defective mitochondrial DNA polymerase.
  262. (2008). Prematurely senescent ARPE-19 cells display features of age-related macular degeneration.
  263. (2006). Pro-apoptotic effect of endogenous H2S on human aorta smooth muscle cells.
  264. (2001). Pro-atherogenic factors induce telomerase inactivation in endothelial cells through an Akt-dependent mechanism.
  265. Prolonged treatment with the AT1 receptor blocker, Valsartan, increases small and large artery compliance in uncomplicated essential hypertension.
  266. (2008). Proteasome modulates mitochondrial function during cellular senescence.
  267. (2007). Protective effect of long-term angiotensin II inhibition.
  268. (2008). Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension.
  269. (2001). Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions.
  270. (2001). Putting the stress on senescence.
  271. (1997). Qualitative and quantitative
  272. Quantitative change in mitochondrial DNA content in various mouse tissues during aging.
  273. (2001). Radiation-induced senescence-like growth arrest requires TP53 function but not telomere shortening.
  274. (1986). Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability.
  275. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
  276. (2003). Ras induces vascular smooth muscle cell senescence and inflammation in human atherosclerosis.
  277. (1999). Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species.
  278. (2001). Reactive oxygen and NF-kappaB in VEGF-induced migration of human vascular smooth muscle cells.
  279. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes.
  280. (2005). Reactive oxygen species as mediators of cellular senescence.
  281. (2007). Reactive oxygen species generation in human vascular smooth muscle cells: a trigger for stress-induced premature senescence. Free Radic Biol Med.
  282. (2003). Reactive oxygen species in the vasculature: molecular and cellular mechanisms.
  283. (2004). Reactive oxygen species in vascular biology: implications in hypertension.
  284. (2001). Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple.
  285. (2008). Redox state and gender differences in vascular smooth muscle cells.
  286. (2003). Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension.
  287. (1998). Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptormediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II.
  288. (2007). Regulation and characteristics of vascular smooth muscle cell phenotypic diversity.
  289. (1995). Regulation of blood pressure by the type 1A angiotensin II receptor gene.
  290. (2001). Regulation of cellular senescence by p53.
  291. (2002). Regulation of mitochondrial biogenesis in skeletal muscle by CaMK.
  292. (2007). Regulatory role of vitamins E and C on extracellular matrix components of the vascular system.
  293. Relevance and safety of telomerase for human tissue engineering.
  294. (2002). Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats.
  295. (2008). Renal mitochondrial impairment is attenuated by AT1 blockade in experimental Type I diabetes.
  296. (2000). Renin-dependent cardiovascular functions and renin-independent blood-brain barrier functions revealed by renindeficient mice.
  297. (2008). Reninangiotensin system inhibitors protect against age-related changes in rat liver mitochondrial DNA content and gene expression.
  298. (2005). Repeated exposure of human skin fibroblasts to UVB at subcytotoxic level triggers premature senescence through the TGF-beta1 signaling pathway.
  299. (1990). Replicative senescence: the human fibroblast comes of age.
  300. (2003). results of a randomized double-blind intervention trial.
  301. (2003). Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles.
  302. (1998). Role of mitochondria in oxidative stress and ageing.
  303. (2005). Role of NAD(P)H oxidase- and mitochondria-derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II.
  304. (1998). Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy.
  305. (2007). Role of oxidative stress in angiotensin II-induced enhanced expression of Gi-α proteins and adenylyl cyclase signaling in A10 vascular smooth muscle cells.
  306. (1999). Role of smooth muscle cell death in advanced coronary primary lesions: implications for plaque instability.
  307. (2006). Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review.
  308. (2008). Screening of senescence-associated genes with specific DNA array reveals the role of IGFBP-3 in premature senescence of human diploid fibroblasts.
  309. (2004). Senescence and functional failure in hematopoietic stem cells.
  310. (2002). Senescence induced by altered telomere state, not telomere loss.
  311. (1998). Senescence of human fibroblasts induced by oncogenic Raf.
  312. (2000). Senescence-associated β-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells.
  313. (2008). Senescence: not just for tumor suppression.
  314. (2005). Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors.
  315. (1995). Senescent human fibroblasts resist programmed cell death, and failure to suppress bcl2 is involved.
  316. (2002). Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction.
  317. (2005). Shelterin: the protein complex that shapes and safeguards human telomeres.
  318. (2004). Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects.
  319. (2000). Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factor?
  320. (1998). Shortened telomere length in white blood cells of patients with IDDM.
  321. (2000). Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells.
  322. (2007). Signaling of mitochondrial biogenesis following oxidant injury.
  323. (1998). Similar gene expression pattern in senescent and hyperoxic-treated fibroblasts.
  324. (2007). Single exposure of human fibroblasts (WI-38) to a subcytotoxic dose of UVB induces premature senescence.
  325. (1994). Sites of superoxide anion production detected by lucigenin in calf pulmonary artery smooth muscle.
  326. (1997). Smooth muscle cell heterogeneity in pulmonary and systemic vessels. Importance in vascular disease.
  327. (2001). Src is an important mediator of extracellular signal-regulated kinase 1/2-dependent growth signaling by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients.
  328. (2008). Statins use a novel Nijmegen breakage syndrome-1-dependent pathway to accelerate DNA repair in vascular smooth muscle cells.
  329. (2008). Stress-induced premature senescence (SIPS)-influence of SIPS on radiotherapy.
  330. (2004). Stress-induced premature senescence in hTERT-expressing ataxia telangiectasia fibroblasts.
  331. (2005). Stress-induced premature senescence in mononuclear cells from patients on long-term hemodialysis.
  332. (2002). Stressinduced premature senescence in BJ and hTERT-BJ1 human foreskin fibroblasts.
  333. (2000). Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants.
  334. (1997). Superoxide anion radical (O2·ˉ), superoxide dismutases, and related matters.
  335. (1999). Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor.
  336. (2008). Sustained hypoxia modulates mitochondrial DNA content in the neonatal rat brain.
  337. (2006). Sustained inhibition of oxidative phosphorylation impairs cell proliferation and induces premature senescence in human fibroblasts.
  338. (2001). Switching and signaling at the telomere.
  339. (2007). Targeting antioxidants to mitochondria by conjugation to lipophilic cations.
  340. (1997). Telomerase activity in normal human endothelial cells.
  341. (2003). Telomerase maintains telomere structure in normal human cells.
  342. (2004). Telomere attrition and accumulation of senescent cells in cultured human endothelial cells.
  343. (2000). Telomere attrition of the human abdominal aorta: relationships with age and atherosclerosis.
  344. (2007). Telomere dysfunction in hypertension.
  345. (2008). Telomere length and obesity.
  346. (2004). Telomere length and possible link to X chromosome.
  347. (1995). Telomere length and replicative aging in human vascular tissues.
  348. (2001). Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity.
  349. (1992). Telomere length predicts replicative capacity of human fibroblasts.
  350. (2007). Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study.
  351. (2001). Telomere shortening in atherosclerosis.
  352. (2004). Telomere shortening in human coronary artery diseases.
  353. (2004). Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21 (CIP1) , but not p16 (INK4a) .
  354. (2001). Telomeres and replicative senescence: Is it only length that counts?
  355. (1990). Telomeres shorten during ageing of human fibroblasts.
  356. (2001). Telomerized human microvasculature is functional in vivo.
  357. (1972). The biologic clock: the mitochondria?
  358. (2004). The clinical use of angiotensinconverting enzyme inhibitors.
  359. (2005). The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle.
  360. (1991). The endothelium of advanced arteriosclerotic plaques in humans.
  361. (2001). The evolution of diverse biological responses to DNA damage: insights from yeast and p53.
  362. (1993). The gene responsible for Werner syndrome may be a cell division "counting" gene.
  363. (1995). The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase.
  364. (2005). The limitations and validities of senescence associated-beta-galactosidase activity as an aging marker for human foreskin fibroblast Hs68 cells.
  365. (1994). The marked disparity between the sizes of angiotensin type 2 receptors from different tissues is related to different degrees of N-glycosylation.
  366. (1985). The mitochondrial electron transport and oxidative phosphorylation system.
  367. (2007). The mitochondrial energy transduction system and the aging process.
  368. (2002). The neutrophil NADPH oxidase.
  369. (2007). The pathways to tumor suppression via route p38.
  370. (2001). The role of mitochondrial calcium overload and energy deficiency in pathogenesis of arterial hypertension.
  371. (2005). The role of nitric oxide in cardiovascular diseases.
  372. (2003). The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications.
  373. (1961). The serial cultivation of human diploid cell strains.
  374. (2005). The signals and pathways activating cellular senescence.
  375. (1979). The smooth muscle cell in culture.
  376. The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells.
  377. (2007). The use of comet assay in measuring DNA damage and repair efficiency in child, adult, and old age populations.
  378. (2004). Thioredoxin reductase 1 is upregulated in atherosclerotic plaques: specific induction of the promoter in human macrophages by oxidized low-density lipoproteins.
  379. (2003). Thioredoxin: a key regulator of cardiovascular homeostasis.
  380. (1998). Tissue-specific expression of human angiotensin II AT1 and AT2 receptors and cellular localization of subtype mRNAs in adult human renal cortex using in situ hybridization.
  381. (2008). Transcriptional paradigms in mammalian mitochondrial biogenesis and function.
  382. (2000). Tumor suppressors and oncogenes in cellular senescence.
  383. (2001). Uncoupling the senescent phenotype from telomere shortening in hydrogen peroxide-treated fibroblasts.
  384. UVB-induced premature senescence of human diploid skin fibroblasts.
  385. Validation of lucigenin (bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems.
  386. (1999). Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production.
  387. (2005). Vascular but not cardiac remodeling is associated with superoxide production in angiotensin II hypertension.
  388. (2004). Vascular cell senescence and vascular aging.
  389. (2005). Vascular hypertrophy in angiotensin II-induced hypertension is mediated by vascular smooth muscle cell-derived H2O2.
  390. (2002). Vascular inflammation and the renin-angiotensin system.
  391. (2003). Vascular NAD(P)H oxidases: specific features, expression, and regulation.
  392. (2002). Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthineoxidase and extracellular superoxide dismutase.
  393. (2008). Vascular smooth muscle cell polyploidy: an adaptive or maladaptive response?
  394. (2006). Vascular smooth muscle cell senescence in atherosclerosis.
  395. (2006). Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress.
  396. (2001). Vascular smooth muscle growth: autocrine growth mechanisms.
  397. (2003). Voltagedependent anion channels control the release of the superoxide anion from mitochondria to cytosol.
  398. (2006). Weight increase and overweight are associated with DNA oxidative damage in skeletal muscle.
  399. (2003). White cell telomere length and risk of premature myocardial infarction.
  400. (2001). Workshop: excess growth and apoptosis: is hypertension a case of accelerated aging of cardiovascular cells?
  401. (2007). Xanthine oxidase-derived extracellular superoxide anions stimulate activator protein 1 activity and hypertrophy in human vascular smooth muscle via c-Jun N-terminal kinase and p38 mitogen-activated protein kinases.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.